Drug Search Results
More Filters [+]

Aciclovir

Alternative Names: aciclovir, acyclovir, zovirax, acyclovir sodium, acyclovir lauriad, me-609, me609, me 609, sitavig, avaclyr, acyclovix, xerese
Latest Update: 2024-11-20
Latest Update Note: Clinical Trial Update

Product Description

Aciclovir is a synthetic compound with a similar molecular structure to purine nucleoside. It has been shown to stop the growth of herpes simplex virus (HSV), Varicella zoster virus (VZV) (the cause of chickenpox and shingles), Epstein-Barr virus (EBV, the cause of infectious mononucleosis), and to a lesser extent cytomegalovirus (CMV).

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Keratitis | Herpes Simplex | Keratitis, Dendritic | Keratitis, Herpetic | Herpes Labialis

Known Adverse Events: Eye Pain | Pain Unspecified | Conjunctivitis | Keratitis | Headache

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aciclovir

Countries in Clinic: Poland, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Herpes Labialis|Herpes Simplex

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OP-LIPC02

P3

Unknown Status

Herpes Labialis

2025-10-25

NCT05098938

P3

Completed

Herpes Simplex|Herpes Labialis

2023-07-19

Recent News Events